Target intelligence / Profile preview

Tyrosine--tRNA ligase, cytoplasmic (YARS1 (also commonly referred to as TyrRS))

Target
YARS1 (also commonly referred to as TyrRS)
Molecular classification
Enzyme, Aminoacyl-tRNA synthetase, Ligase (specifically, forms carbon–oxygen bonds in tRNA and related compounds)[3][4]
01

Overview

Tyrosine--tRNA ligase, cytoplasmic (YARS1), also known as tyrosyl-tRNA synthetase or TyrRS, is an essential enzyme that catalyzes the two-step attachment of L‑tyrosine to its cognate tRNATyr during protein biosynthesis. This reaction is fundamental for translating genetic information into proteins by ensuring accurate incorporation of tyrosine at positions specified by mRNAs. The enzyme first activates tyrosine with ATP forming a Tyr‑AMP intermediate before transferring it onto tRNATyr. Beyond this canonical role in translation, YARS1 has additional functions including regulation of nuclear poly(ADP-ribosyl)ation through interaction with PARP1—especially upon binding small molecules such as resveratrol—and may exert cytokine-like or proangiogenic effects via proteolytic fragments outside the context of protein synthesis[1][3][4][6].

Other names
Tyrosyl-tRNA synthetaseYARS1SYYC_HUMAN (UniProt entry name)EC 6.1.1.1
02

Mechanism of action

For inhibitors like resveratrol: - Inhibition of aminoacylation activity by direct binding, leading to relocalization from cytoplasm to nucleus where it stimulates PARP1-mediated poly(ADP-ribosyl)ation independent of aminoacylation function[1].

03

Biological functions

Catalyzes the attachment of tyrosine to its cognate tRNA(Tyr) during protein synthesis[1][3]Translates the genetic code by linking amino acids to their corresponding tRNAs[3]Positive regulator of poly(ADP-ribosyl)ation in the nucleus, independently of its canonical ligase activity[1]May have cytokine-like activity and proangiogenic roles via proteolytic fragments[6]
04

Disease associations

Cancer (due to proangiogenic and immune-modulatory activities)[6]Other (potential involvement in translation-related disorders; specific disease associations are still under investigation)
05

Safety considerations

Potential safety concerns could include disruption of global protein synthesis if inhibited systemically due to essential role in translationoff-target effects on nuclear signaling pathways may also be relevant but are not well characterized.
06

Interacting drugs

resveratrol

Beyond the preview

Go deeper on Tyrosine--tRNA ligase, cytoplasmic (YARS1 (also commonly referred to as TyrRS)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyrosine--tRNA ligase, cytoplasmic (YARS1 (also commonly referred to as TyrRS)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call